Fc engineering to improve the function of therapeutic antibodies

Current Pharmaceutical Biotechnology

Volumn 17, Issue 15, 2016, Pages 1298-1314

  Mimoto, Futa ^a   Kuramochi, Taichi ^b   Katada, Hitoshi ^a   Igawa, Tomoyuki ^a   Hattori, Kunihiro ^a  

^a CHUGAI PHARMACEUTICAL CO LTD   (Japan)

^b Chugai Pharmabody Research Pte Ltd   (Singapore)

Author keywords

Antibody; Antibody engineering; Fc engineering; Protein engineering; Therapeutic antibody

Indexed keywords

ALEMTUZUMAB; ANTIBODY; CD137 ANTIGEN; CD40 ANTIGEN; FC RECEPTOR; IMMUNOGLOBULIN G ANTIBODY; PROTEINASE; RHEUMATOID FACTOR; RITUXIMAB; TEPLIZUMAB; TRASTUZUMAB; VISILIZUMAB;

AGONISTIC ACTIVITY; ALLOTYPE; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; BINDING AFFINITY; BIOENGINEERING; BIOLOGICAL ACTIVITY; CHEMICAL REACTION; CHROMATOGRAPHY; CHRONIC LYMPHATIC LEUKEMIA; COMPLEMENT DEPENDENT CYTOTOXICITY; GENE MUTATION; HUMAN; HUMORAL IMMUNE DEFICIENCY; MOLECULAR STABILITY; NATURAL KILLER CELL; NONHUMAN; REVIEW;

EID: 85009207935     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/1389201017666160824161854     Document Type: Review

References (148)

1. Elvin, J.G.; Couston, R.G.; van der Walle, C.F. Therapeutic antibodies: Market considerations, disease targets and bioprocessing. Int. J. Pharm., 2013, 440(1), 83-98.
2. Reichert, J.M. Antibodies to watch in 2015. MAbs, 2015, 7(1), 1-8.
3. Igawa, T.; Tsunoda, H.; Kuramochi, T.; Sampei, Z.; Ishii, S.; Hattori, K. Engineering the variable region of therapeutic IgG antibodies. MAbs, 2011, 3(3), 243-252.
4. Beck, A.; Wurch, T.; Bailly, C.; Corvaia, N. Strategies and challenges for the next generation of therapeutic antibodies. Nat. Rev. Immunol., 2010, 10(5), 345-352.
5. Lazar, G.A.; Dang, W.; Karki, S.; Vafa, O.; Peng, J.S.; Hyun, L.; Chan, C.; Chung, H.S.; Eivazi, A.; Yoder, S.C.; Vielmetter, J.; Carmichael, D.F.; Hayes, R.J.; Dahiyat, B.I. Engineered antibody Fc variants with enhanced effector function. Proc. Natl. Acad. Sci. USA, 2006, 103(11), 4005-4010.
6. Stavenhagen, J.B.; Gorlatov, S.; Tuaillon, N.; Rankin, C.T.; Li, H.; Burke, S.; Huang, L.; Vijh, S.; Johnson, S.; Bonvini, E.; Koenig, S. Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcγ receptors. Cancer Res., 2007, 67(18), 8882-8890.
7. Shields, R.L.; Lai, J.; Keck, R.; O’Connell, L.Y.; Hong, K.; Meng Y.G.; Weikert, S.H.; Presta, L.G. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcγ RIII and antibody-dependent cellular toxicity. J. Biol. Chem., 2002, 277(30), 26733-26740.
8. Shinkawa, T.; Nakamura, K.; Yamane, N.; Shoji-Hosaka, E.; Kanda, Y.; Sakurada, M.; Uchida, K.; Anazawa, H.; Satoh, M.; Yamasaki, M.; Hanai, N.; Shitara, K. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J. Biol. Chem., 2003, 278(5), 3466-3473.
9. Shields, R.L.; Namenuk A.K.; Hong, K.; Meng, Y.G.; Rae, J.; Briggs, J.; Xie, D.; Lai, J.; Stadlen, A.; Li, B.; Fox, J.A.; Presta, L.G. High resolution mapping of the binding site on human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and design of IgG1 variants with improved binding to the FcγR. J. Biol. Chem., 2001, 276(9), 6591-6604.
10. Moore, G.L.; Chen, H.; Karki, S.; Lazar, G.A. Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions. MAbs, 2010, 2(2), 181-189.
11. Idusogie, E.E.; Wong, P.Y.; Presta, L.G.; Gazzano-Santoro, H.; Totpal K.; Ultsch M.; Mulkerrin, M.G. Engineered antibodies with increased activity to recruit complement. J. Immunol., 2001, 166(4), 2571-2575.
12. Heyman, B. Feedback regulation by IgG antibodies. Immunol. Lett., 2003, 88(2), 157-161.
13. Nimmerjahn, F.; Ravetch, J.V. Fcγ receptors as regulators of immune responses. Nat. Rev. Immunol., 2008, 8(1), 34-47.
14. Horton, H.M.; Chu, S.Y.; Ortiz, E.C.; Pong, E.; Cemerski, S.; Leung, I. W.; Jacob, N.; Zalevsky, J.; Desjarlais, J.R.; Stohl, W.; Szymkowski, D.E. Antibody-mediated coengagement of FcγRIIb and B cell receptor complex suppresses humoral immunity in systemic lupus erythematosus. J. Immunol., 2011, 186(7), 4223-4233.
15. Chu, S.Y.; Yeter, K.; Kotha, R.; Pong, E.; Miranda, Y.; Phung, S.; Chen, H.; Lee S.H.; Leung, I.; Bonzon, C.; Desjarlais, J.R.; Stohl, W.; Szymkowski, D.E. Suppression of rheumatoid arthritis B cells by XmAb5871, an anti-CD19 antibody that coengages B cell antigen receptor complex and Fcγ receptor IIb inhibitory receptor. Arthritis Rheumatol., 2014, 66(5), 1153-1164.
16. Chu, S.Y.; Vostiar, I.; Karki, S.; Moore, G.L.; Lazar, G.A.; Pong, E.; Joyce, P.F.; Szymkowski, D.E.; Desjarlais, J.R. Inhibition of B cell receptor-mediated activation of primary human B cells by coengagement of CD19 and FcγRIIb with Fc-engineered antibodies. Mol. Immunol., 2008, 45(15), 3926-3933.
17. Mimoto, F.; Katada, H.; Kadono, S.; Igawa, T.; Kuramochi, T.; Muraoka, M.; Wada, Y.; Haraya, K.; Miyazaki, T.; Hattori, K. Engineered antibody Fc variant with selectively enhanced FcγRIIb binding over both FcγRIIa(R131) and FcγRIIa(H131). Protein Eng. Des. Sel., 2013, 26(10), 589-598.
18. White A.L.; Chan, H.T.; French, R.R.; Beers, S.A.; Cragg, M.S.; Johnson, P.W.; Glennie, M.J. FcγRIIB controls the potency of agonistic anti-TNFR mAbs. Cancer Immunol. Immunother., 2013, 62(5), 941-948.
19. Wilson, N.S.; Yang, B.; Yang, A.; Loeser, S.; Marsters, S.; Lawrence, D.; Li, Y.; Pitti, R.; Totpal, K.; Yee, S.; Ross, S.; Vernes, J.M.; Lu, Y.; Adams, C.; Offringa, R.; Kelley, B.; Hymowitz, S.; Daniel, D.; Meng, G.; Ashkenazi, A. An Fcγ receptor-dependent mechanism drives antibody-mediated targetreceptor signaling in cancer cells. Cancer Cell, 2011, 19(1), 101-113.
20. Li, F.; Ravetch, J.V. Apoptotic and antitumor activity of death receptor antibodies require inhibitory Fcγ receptor engagement. Proc. Natl. Acad. Sci. USA, 2012, 109(27), 10966-10971.
21. Xu, Y.; Szalai, A.J.; Zhou, T.; Zinn, K.R.; Chaudhuri, T.R.; Li, X.; Koopman, W.J.; Kimberly, R.P. FcγRs modulate cytotoxicity of anti-Fas antibodies: Implications for agonistic antibody-based therapeutics. J. Immunol., 2003, 171(2), 562-568.
22. Ward, E.S.; Zhou, J.; Ghetie, V.; Ober, R.J. Evidence to support the cellular mechanism involved in serum IgG homeostasis in humans. Int. Immunol., 2003, 15(2), 187-195.
23. Petkova, S.B.; Akilesh, S.; Sproule, T.J.; Christianson, G.J.; Al Khabbaz, H.; Brown, A.C.; Presta, L.G.; Meng, Y.G.; Roopenian, D.C. Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: Potential application in humorally mediated autoimmune disease. Int. Immunol., 2006, 18(12), 1759-1769.
24. Yeung, Y.A.; Leabman, M.K.; Marvin, J.S.; Qiu, J.; Adams, C.W.; Lien, S.; Starovasnik, M.A.; Lowman, H.B. Engineering human IgG1 affinity to human neonatal Fc receptor: Impact of affinity improvement on pharmacokinetics in primates. J. Immunol., 2009, 182(12), 7663-7671.
25. Hinton, P.R.; Johlfs, M.G.; Xiong, J.M.; Hanestad, K.; Ong K.C.; Bullock, C.; Keller, S.; Tang, M.T.; Tso, J.Y.; Vasquez, M.; Tsurushita, N. Engineered human IgG antibodies with longer serum half-lives in primates. J. Biol. Chem., 2004, 279(8), 6213-6216.
26. Robbie, G.J.; Criste, R.; Dall’acqua, W.F.; Jensen, K.; Patel, N.K.; Losonsky, G.A.; Griffin, M.P. A novel investigational Fc-modified humanized monoclonal antibody, motavizumab-YTE, has an extended half-life in healthy adults. Antimicrob. Agents Chemother., 2013, 57(12), 6147-6153.
27. Zalevsky, J.; Chamberlain, A.K.; Horton, H.M.; Karki, S.; Leung, I.W.; Sproule, T.J.; Lazar, G.A.; Roopenian, D.C.; Desjarlais, J.R. Enhanced antibody half-life improves in vivo activity. Nat. Biotechnol., 2010, 28(2), 157-159.
28. Igawa, T.; Maeda, A.; Haraya, K.; Tachibana, T.; Iwayanagi, Y.; Mimoto, F.; Higuchi, Y.; Ishii, S.; Tamba, S.; Hironiwa, N.; Nagano, K.; Wakabayashi, T.; Tsunoda, H.; Hattori, K. Engineered monoclonal antibody with novel antigen-sweeping activity in vivo. PLoS One, 2013, 8(5), e63236.
29. Klein, C.; Sustmann, C.; Thomas, M.; Stubenrauch, K.; Croasdale, R.; Schanzer, J.; Brinkmann, U.; Kettenberger, H.; Regula, J.T.; Schaefer, W. Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies. MAbs, 2012, 4(6), 653-663.
30. von Pawel-Rammingen, U.; Johansson, B.P.; Bjorck, L. IdeS, a novel streptococcal cysteine proteinase with unique specificity for immunoglobulin G. EMBO J., 2002, 21(7), 1607-1615.
31. Gearing, A.J.; Thorpe, S.J.; Miller, K.; Mangan, M.; Varley, P.G.; Dudgeon, T.; Ward, G.; Turner, C.; Thorpe, R. Selective cleavage of human IgG by the matrix metalloproteinases, matrilysin and stromelysin. Immunol. Lett., 2002, 81(1), 41-48.
32. Ryan, M.H.; Petrone, D.; Nemeth, J.F.; Barnathan, E.; Bjorck L.; Jordan, R.E. Proteolysis of purified IgGs by human and bacterial enzymes in vitro and the detection of specific proteolytic fragments of endogenous IgG in rheumatoid synovial fluid. Mol. Immunol., 2008, 45(7), 1837-1846.
33. Vincents, B.; von Pawel-Rammingen, U.; Bjorck, L.; Abrahamson, M. Enzymatic characterization of the streptococcal endopeptidase, IdeS, reveals that it is a cysteine protease with strict specificity for IgG cleavage due to exosite binding. Biochemistry, 2004, 43(49), 15540-15549.
34. Brezski, R.J.; Vafa, O.; Petrone, D.; Tam, S.H.; Powers, G.; Ryan, M.H.; Luongo, J.L.; Oberholtzer, A.; Knight, D.M.; Jordan, R.E. Tumor-associated and microbial proteases compromise host IgG effector functions by a single cleavage proximal to the hinge. Proc. Natl. Acad. Sci. USA, 2009, 106(42), 17864-17869.
35. Fan, X.; Brezski, R.J.; Fa, M.; Deng, H.; Oberholtzer, A.; Gonzalez, A.; Dubinsky, W. P.; Strohl, W.R.; Jordan, R.E.; Zhang, N.; An, Z. A single proteolytic cleavage within the lower hinge of trastuzumab reduces immune effector function and in vivo efficacy. Breast Cancer Res., 2012, 14(4), R116.
36. Brezski, R.J.; Oberholtzer, A.; Strake, B.; Jordan, R.E. The in vitro resistance of IgG2 to proteolytic attack concurs with a comparative paucity of autoantibodies against peptide analogs of the IgG2 hinge. MAbs, 2011, 3(6), 558-567.
37. Kinder, M.; Greenplate, A.R.; Grugan, K.D.; Soring, K.L.; Heeringa, K.A.; McCarthy, S.G.; Bannish, G.; Perpetua, M.; Lynch, F.; Jordan, R.E.; Strohl, W.R.; Brezski, R.J. Engineered protease-resistant antibodies with selectable cell-killing functions. J. Biol. Chem., 2013, 288(43), 30843-30854.
38. Walker, M.; Makropoulos, D.; Achuthanandam, R.; Bugelski, P.J. Recent advances in the understanding of drug-mediated infusion reactions and cytokine release syndrome. Curr. Opin. Drug Discov. Devel., 2010, 13(1), 124-135.
39. Bugelski, P.J.; Achuthanandam, R.; Capocasale, R.J.; Treacy, G.; Bouman-Thio, E. Monoclonal antibody-induced cytokine-release syndrome. Expert Rev. Clin. Immunol., 2009, 5(5), 499-521.
40. Mimoto, F.; Igawa, T.; Kuramochi, T.; Katada, H.; Kadono, S.; Kamikawa, T.; Shida-Kawazoe, M.; Hattori, K. Novel asymmetrically engineered antibody Fc variant with superior FcγR binding affinity and specificity compared with afucosylated Fc variant. MAbs, 2013, 5(2), 229-236.
41. Liu, Z.; Gunasekaran, K.; Wang, W.; Razinkov, V.; Sekirov, L.; Leng, E.; Sweet, H.; Foltz, I.; Howard, M.; Rousseau, A.M.; Kozlosky, C.; Fanslow W.; Yan, W. Asymmetrical Fc engineering greatly enhances antibody-dependent cellular cytotoxicity (ADCC) effector function and stability of the modified antibodies. J. Biol. Chem., 2014, 289(6), 3571-3590.
42. Dall’Acqua, W.F.; Cook, K.E.; Damschroder, M.M.; Woods, R.M.; Wu, H. Modulation of the effector functions of a human IgG1 through engineering of its hinge region. J. Immunol., 2006, 177(2), 1129-1138.
43. Jung, S.T.; Reddy, S.T.; Kang, T.H.; Borrok, M.J.; Sandlie, I.; Tucker, P.W.; Georgiou, G. Aglycosylated IgG variants expressed in bacteria that selectively bind FcγRI potentiate tumor cell killing by monocyte-dendritic cells. Proc. Natl. Acad. Sci. USA, 2010, 107(2), 604-609.
44. Natsume, A.; In, M.; Takamura, H.; Nakagawa, T.; Shimizu, Y.; Kitajima, K.; Wakitani, M.; Ohta, S.; Satoh, M.; Shitara, K.; Niwa, R. Engineered antibodies of IgG1/IgG3 mixed isotype with enhanced cytotoxic activities. Cancer Res., 2008, 68(10), 3863-3872.
45. Vaccaro, C.; Zhou, J.; Ober, R.J.; Ward, E.S. Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels. Nat. Biotechnol., 2005, 23(10), 1283-1288.
46. Carter, P. Bispecific human IgG by design. J. Immunol. Methods, 2001, 248(1-2), 7-15.
47. Igawa, T.; Tsunoda, H. Methods for producing polypeptides by regulating polypeptide association. WO2006,106905. Octorber 12, 2006.
48. Gunasekaran, K.; Pentony, M.; Shen, M.; Garrett, L.; Forte, C.; Woodward, A.; Ng, S. B.; Born, T.; Retter, M.; Manchulenko, K.; Sweet, H.; Foltz, I. N.; Wittekind, M.; Yan, W. Enhancing antibody Fc heterodimer formation through electrostatic steering effects: applications to bispecific molecules and monovalent IgG. J. Biol. Chem., 2010, 285(25), 19637-19646.
49. vanderNeut Kolfschoten, M.; Schuurman, J.; Losen, M.; Bleeker, W.K.; Martinez-Martinez, P.; Vermeulen, E.; den Bleker, T.H.; Wiegman, L.; Vink, T.; Aarden, L.A.; De Baets, M.H.; van de Winkel, J.G.; Aalberse, R.C.; Parren, P.W. Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange. Science, 2007, 317(5844), 1554-1557.
50. Labrijn, A.F.; Meesters, J.I.; de Goeij, B.E.; van den Bremer, E.T.; Neijssen, J.; van Kampen, M.D.; Strumane, K.; Verploegen, S.; Kundu, A.; Gramer, M.J.; van Berkel, P.H.; van de Winkel, J.G.; Schuurman, J.; Parren, P.W. Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange. Proc. Natl. Acad. Sci. USA, 2013, 110(13), 5145-5150.
51. Strop, P.; Ho, W.H.; Boustany, L.M.; Abdiche, Y.N.; Lindquist, K.C.; Farias, S.E.; Rickert, M.; Appah, C.T.; Pascua, E.; Radcliffe, T.; Sutton, J.; Chaparro-Riggers, J.; Chen, W.; Casas, M.G.; Chin, S.M.; Wong, O.K.; Liu, S.H.; Vergara, G.; Shelton, D.; Rajpal, A.; Pons, J. Generating bispecific human IgG1 and IgG2 antibodies from any antibody pair. J. Mol. Biol., 2012, 420(3), 204-219.
52. Shatz, W.; Chung, S.; Li, B.; Marshall, B.; Tejada, M.; Phung, W.; Sandoval, W.; Kelley, R.F.; Scheer, J.M. Knobs-into-holes antibody production in mammalian cell lines reveals that asymmetric afucosylation is sufficient for full antibody-dependent cellular cytotoxicity. MAbs, 2013, 5(6), 872-881.
53. Mueller, J.P.; Giannoni, M.A.; Hartman, S.L.; Elliott, E.A.; Squinto, S.P.; Matis, L.A.; Evans, M.J. Humanized porcine VCAM-specific monoclonal antibodies with chimeric IgG2/G4 constant regions block human leukocyte binding to porcine endothelial cells. Mol. Immunol., 1997, 34(6), 441-452.
54. Rother, R.P.; Rollins, S.A.; Mojcik, C.F.; Brodsky, R.A.; Bell, L. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat. Biotechnol., 2007, 25(11), 1256-1264.
55. An, Z.; Forrest, G.; Moore, R.; Cukan, M.; Haytko, P.; Huang, L.; Vitelli, S.; Zhao, J.Z.; Lu, P.; Hua, J.; Gibson, C.R.; Harvey, B.R.; Montgomery, D.; Zaller, D.; Wang, F.; Strohl, W. IgG2m4, an engineered antibody isotype with reduced Fc function. MAbs, 2009, 1(6), 572-579.
56. Nose, M.; Wigzell, H. Biological significance of carbohydrate chains on monoclonal antibodies. Proc. Natl. Acad. Sci. USA, 1983, 80(21), 6632-6636.
57. Alegre, M.L.; Peterson, L.J.; Xu, D.; Sattar, H.A.; Jeyarajah, D.R.; Kowalkowski, K.; Thistlethwaite, J.R.; Zivin R.A.; Jolliffe L.; Bluestone J.A. A non-activating “humanized” anti-CD3 monoclonal antibody retains immunosuppressive properties in vivo. Transplantation, 1994, 57(11), 1537-1543.
58. Hezareh, M.; Hessell, A.J.; Jensen, R.C.; van deWinkel, J.G.; Parren, P.W. Effector function activities of a panel of mutants of a broadly neutralizing antibody against human immunodeficiency virus type 1. J. Virol., 2001, 75(24), 12161-12168.
59. Vafa, O.; Gilliland, G.L.; Brezski, R.J.; Strake, B.; Wilkinson, T.; Lacy, E.R.; Scallon, B.; Teplyakov, A.; Malia, T.J.; Strohl, W.R. An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations. Methods, 2014, 65(1), 114-126.
60. Bruhns, P.; Iannascoli, B.; England, P.; Mancardi, D. A.; Fernandez, N.; Jorieux, S.; Daeron, M. Specificity and affinity of human Fcγ receptors and their polymorphic variants for human IgG subclasses. Blood, 2009, 113(16), 3716-3725.
61. Musolino, A.; Naldi, N.; Bortesi, B.; Pezzuolo, D.; Capelletti, M.; Missale, G.; Laccabue, D.; Zerbini, A.; Camisa, R.; Bisagni, G.; Neri, T.M.; Ardizzoni, A. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J. Clin. Oncol., 2008, 26(11), 1789-1796.
62. Cartron, G.; Dacheux, L.; Salles, G.; Solal-Celigny, P.; Bardos, P.; Colombat, P.; Watier, H. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene. Blood, 2002, 99(3), 754-758.
63. Hurvitz, S.A.; Betting, D.J.; Stern, H.M.; Quinaux, E.; Stinson, J.; Seshagiri, S.; Zhao, Y.; Buyse, M.; Mackey, J.; Driga, A.; Damaraju, S.; Sliwkowski, M.X.; Robert, N.J.; Valero, V.; Crown, J.; Falkson, C.; Brufsky, A.; Pienkowski, T.; Eiermann, W.; Martin, M.; Bee, V.; Marathe, O.; Slamon, D.J.; Timmerman, J.M. Analysis of Fcγ receptor IIIa and IIa polymorphisms: Lack of correlation with outcome in trastuzumab-treated breast cancer patients. Clin. Cancer Res., 2012, 18(12), 3478-3486.
64. Iida, S.; Misaka, H.; Inoue, M.; Shibata, M.; Nakano, R.; Yamane-Ohnuki, N.; Wakitani, M.; Yano, K.; Shitara, K.; Satoh, M. Nonfucosylated therapeutic IgG1 antibody can evade the inhibitory effect of serum immunoglobulin G on antibody-dependent cellular cytotoxicity through its high binding to FcγRIIIa. Clin. Cancer Res., 2006, 12(9), 2879-2887.
65. Yamane-Ohnuki, N.; Kinoshita S.; Inoue-Urakubo, M.; Kusunoki, M.; Iida, S.; Nakano, R.; Wakitani, M.; Niwa, R.; Sakurada, M.; Uchida, K.; Shitara, K.; Satoh, M. Establishment of FUT8 knockout Chinese hamster ovary cells: an ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity. Biotechnol. Bioeng., 2004, 87(5), 614-622.
66. Ferrara, C.; Brunker, P.; Suter, T.; Moser, S.; Puntener, U.; Umana, P. Modulation of therapeutic antibody effector functions by glycosylation engineering: Influence of Golgi enzyme localization domain and co-expression of heterologous beta1, 4-Nacetylglucosaminyltransferase III and Golgi alpha-mannosidase II. Biotechnol. Bioeng., 2006, 93(5), 851-861.
67. Zalevsky, J.; Leung, I.W.; Karki, S.; Chu S.Y.; Zhukovsky, E.A.; Desjarlais, J.R.; Carmichael, D.F.; Lawrence C.E. The impact of Fc engineering on an anti-CD19 antibody: Increased Fcγ receptor affinity enhances B-cell clearing in nonhuman primates. Blood, 2009, 113(16), 3735-3743.
68. Clynes, R.A.; Towers, T.L.; Presta, L.G.; Ravetch, J.V. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat. Med., 2000, 6(4), 443-446.
69. Green, S.K.; Karlsson, M.C.; Ravetch, J.V.; Kerbel, R.S. Disruption of cell-cell adhesion enhances antibody-dependent cellular cytotoxicity: Implications for antibody-based therapeutics of cancer. Cancer Res., 2002, 62(23), 6891-6900.
70. Radaev, S.; Motyka, S.; Fridman, W.H.; Sautes-Fridman, C.; Sun, P.D. The structure of a human type III Fcγ receptor in complex with Fc. J. Biol. Chem., 2001, 276(19), 16469-16477.
71. Repp, R.; Kellner, C.; Muskulus, A.; Staudinger, M.; Nodehi, S.M.; Glorius, P.; Akramiene, D.; Dechant, M.; Fey, G.H.; van Berkel, P.H.; van de Winkel, J.G.; Parren, P.W.; Valerius, T.; Gramatzki, M.; Peipp, M. Combined Fc-protein-and Fc-glyco-engineering of scFv-Fc fusion proteins synergistically enhances CD16a binding but does not further enhance NK-cell mediated ADCC. J. Immunol. Methods, 2011, 373(1-2), 67-78.
72. Walker, M.R.; Lund, J.; Thompson, K.M.; Jefferis, R. Aglycosylation of human IgG1 and IgG3 monoclonal antibodies can eliminate recognition by human cells expressing FcγRI and/or FcγRII receptors. Biochem. J., 1989, 259(2), 347-353.
73. Golay, J.; Da Roit, F.; Bologna, L.; Ferrara, C.; Leusen, J.H.; Rambaldi, A.; Klein, C.; Introna, M. Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab. Blood, 2013, 122(20), 3482-3491.
74. Richards, J.O.; Karki, S.; Lazar, G.A.; Chen, H.; Dang, W.; Desjarlais, J.R. Optimization of antibody binding to FcγRIIa enhances macrophage phagocytosis of tumor cells. Mol. Cancer Ther., 2008, 7(8), 2517-2527.
75. Takai, H.; Kato, A.; Kinoshita, Y.; Ishiguro, T.; Takai, Y.; Ohtani, Y.; Sugimoto, M.; Suzuki, M. Histopathological analyses of the antitumor activity of anti-glypican-3 antibody (GC33) in human liver cancer xenograft models: The contribution of macrophages. Cancer Biol. Ther., 2009, 8(10), 930-938.
76. Oflazoglu, E.; Stone, I.J.; Gordon, K.A.; Grewal, I.S.; van Rooijen, N.; Law C.L.; Gerber, H.P. Macrophages contribute to the antitumor activity of the anti-CD30 antibody SGN-30. Blood, 2007, 110(13), 4370-4372.
77. Mimoto, F.; Kadono, S.; Katada, H.; Igawa, T.; Kamikawa, T.; Hattori, K. Crystal structure of a novel asymmetrically engineered Fc variant with improved affinity for FcγRs. Mol. Immunol., 2014, 58(1), 132-138.
78. Beck, A.; Reichert, J.M. Marketing approval of mogamulizumab: a triumph for glyco-engineering. MAbs, 2012, 4(4), 419-425.
79. Abraham, J.; Stegner, M. Obinutuzumab for previously untreated chronic lymphocytic leukemia. J. Community Support Oncol., 2014, 12(4), 118-120.
80. Rogers, K.A.; Jones, J.A. Obinutuzumab for the treatment of chronic lymphocytic leukemia. Drugs Today (Barc), 2014, 50(6), 407-419.
81. Zhou, X.; Hu, W.; Qin, X. The role of complement in the mechanism of action of rituximab for B-cell lymphoma: Implications for therapy. Oncologist, 2008, 13(9), 954-966.
82. Wang, S.Y.; Veeramani, S.; Racila, E.; Cagley, J.; Fritzinger, D.C.; Vogel, C.W.; St John, W.; Weiner, G.J. Depletion of the C3 component of complement enhances the ability of rituximab-coated target cells to activate human NK cells and improves the efficacy of monoclonal antibody therapy in an in vivo model. Blood, 2009, 114(26), 5322-5330.
83. Pawluczkowycz, A.W.; Beurskens, F.J.; Beum, P.V.; Lindorfer, M.A.; van de Winkel, J.G.; Parren, P.W.; Taylor, R.P. Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX. J. Immunol., 2009, 183(1), 749-758.
84. Chu, S.Y.; Horton, H.M.; Pong, E.; Leung, I.W.; Chen, H.; Nguyen, D.H.; Bautista, C.; Muchhal, U.S.; Bernett, M.J.; Moore, G.L.; Szymkowski, D.E.; Desjarlais, J.R. Reduction of total IgE by targeted coengagement of IgE B-cell receptor and FcγRIIb with Fcengineered antibody. J. Allergy Clin. Immunol., 2012, 129(4), 1102-1115.
85. Hayashi, N.; Tsukamoto, Y.; Sallas, W.M.; Lowe, P.J. A mechanism-based binding model for the population pharmacokinetics and pharmacodynamics of omalizumab. Br. J. Clin. Pharmacol., 2007, 63(5), 548-561.
86. Hochhaus, G.; Brookman, L.; Fox, H.; Johnson, C.; Matthews, J.; Ren, S.; Deniz, Y. Pharmacodynamics of omalizumab: implications for optimised dosing strategies and clinical efficacy in the treatment of allergic asthma. Curr. Med. Res. Opin., 2003, 19(6), 491-498.
87. Ganesan, L.P.; Kim, J.; Wu, Y.; Mohanty, S.; Phillips, G.S.; Birmingham, D.J.; Robinson, J.M.; Anderson, C.L. FcγRIIb on liver sinusoidal endothelium clears small immune complexes. J. Immunol., 2012, 189(10), 4981-4988.
88. Li, S.Y.; Liu, Y. Immunotherapy of melanoma with the immune costimulatory monoclonal antibodies targeting CD137. Clin. Pharmacol., 2013, 5(Suppl 1), 47-53.
89. Vonderheide, R.H.; Burg, J.M.; Mick, R.; Trosko, J.A.; Li, D.; Shaik, M.N.; Tolcher, A.W.; Hamid, O. Phase I study of the CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumors. Oncoimmunology, 2013, 2(1), e23033.
90. Bensinger, W.; Maziarz, R.T.; Jagannath, S.; Spencer, A.; Durrant, S.; Becker, P. S.; Ewald, B.; Bilic, S.; Rediske, J.; Baeck, J.; Stadtmauer, E.A. A phase 1 study of lucatumumab, a fully human anti-CD40 antagonist monoclonal antibody administered intravenously to patients with relapsed or refractory multiple myeloma. Br. J. Haematol., 2012, 159(1), 58-66.
91. Roopenian, D.C.; Akilesh, S. FcRn: the neonatal Fc receptor comes of age. Nat. Rev. Immunol., 2007, 7(9), 715-725.
92. Monnet, C.; Jorieux, S.; Souyris, N.; Zaki, O.; Jacquet, A.; Fournier, N.; Crozet, F.; de Romeuf, C.; Bouayadi, K.; Urbain, R.; Behrens, C.K.; Mondon, P.; Fontayne, A. Combined glyco-and protein-Fc engineering simultaneously enhance cytotoxicity and half-life of a therapeutic antibody. MAbs, 2014, 6(2), 422-436.
93. Datta-Mannan, A.; Witcher, D.R.; Tang, Y.; Watkins, J.; Jiang, W.; Wroblewski, V.J. Humanized IgG1 variants with differential binding properties to the neonatal Fc receptor: Relationship to pharmacokinetics in mice and primates. Drug Metab. Dispos., 2007, 35(1), 86-94.
94. Patel, D.A.; Puig-Canto, A.; Challa, D.K.; Perez Montoyo, H.; Ober, R.J.; Ward, E.S. Neonatal Fc receptor blockade by Fc engineering ameliorates arthritis in a murine model. J. Immunol., 2011, 187(2), 1015-1022.
95. Igawa T.; Mimoto F.; Hattori K. pH-dependent antigen-binding antibodies as a novel therapeutic modality. Biochim. Biophys. Acta, 2014, 1844(11), 1943-1950.
96. Xiao, J.J.; Krzyzanski, W.; Wang, Y.M.; Li, H.; Rose, M.J.; Ma, M.; Wu, Y.; Hinkle, B.; Perez-Ruixo, J.J. Pharmacokinetics of antihepcidin monoclonal antibody Ab 12B9m and hepcidin in cynomolgus monkeys. AAPS J., 2010, 12(4), 646-657.
97. Igawa, T.; Ishii, S.; Tachibana, T.; Maeda, A.; Higuchi, Y.; Shimaoka, S.; Moriyama, C.; Watanabe, T.; Takubo, R.; Doi, Y.; Wakabayashi, T.; Hayasaka, A.; Kadono, S.; Miyazaki, T.; Haraya, K.; Sekimori, Y.; Kojima, T.; Nabuchi, Y.; Aso, Y.; Kawabe, Y.; Hattori, K. Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization. Nat. Biotechnol., 2010, 28(11), 1203-1207.
98. Mousavi, S.A.; Sporstol, M.; Fladeby, C.; Kjeken, R.; Barois, N.; Berg, T. Receptor-mediated endocytosis of immune complexes in rat liver sinusoidal endothelial cells is mediated by FcγRIIb2. Hepatology, 2007, 46(3), 871-884.
99. Iwayanagi Y.; Igawa T.; Maeda A.; Haraya K.; Wada N. A.; Shibahara N.; Ohmine K.; Nambu T.; Nakamura G.; Mimoto F.; Katada H.; Ito S.; Tachibana T.; Jishage K.; Hattori K. inhibitory FcgammaRIIb-mediated soluble antigen clearance from plasma by a pH-dependent antigen-binding antibody and its enhancement by Fc engineering. J. Immunol., 2015, 195(7), 3198-3205.
100. Chan, A.C.; Carter, P.J. Therapeutic antibodies for autoimmunity and inflammation. Nat. Rev. Immunol., 2010, 10(5), 301-316.
101. Merchant, A.M.; Zhu, Z.; Yuan, J.Q.; Goddard, A.; Adams, C.W.; Presta, L.G.; Carter, P. An efficient route to human bispecific IgG. Nat. Biotechnol., 1998, 16(7), 677-681.
102. Schaefer, W.; Regula, J.T.; Bahner, M.; Schanzer, J.; Croasdale, R.; Durr, H.; Gassner, C.; Georges, G.; Kettenberger, H.; Imhof-Jung, S.; Schwaiger, M.; Stubenrauch, K.G.; Sustmann, C.; Thomas, M.; Scheuer, W.; Klein, C. Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies. Proc. Natl. Acad. Sci. USA, 2011, 108(27), 11187-11192.
103. Lewis, S.M.; Wu, X.; Pustilnik, A.; Sereno, A.; Huang, F.; Rick, H.L.; Guntas G.; Leaver-Fay, A.; Smith, E.M.; Ho, C.; Hansen-Estruch, C.; Chamberlain, A.K.; Truhlar, S.M.; Conner, E.M.; Atwell, S.; Kuhlman, B.; Demarest, S.J. Generation of bispecific IgG antibodies by structure-based design of an orthogonal Fab interface. Nat. Biotechnol., 2014, 32(2), 191-198.
104. Ridgway, J.B.; Presta, L.G.; Carter, P. ‘Knobs-into-holes’ engineering of antibody CH3 domains for heavy chain heterodimerization. Protein Eng., 1996, 9(7), 617-621.
105. Atwell, S.; Ridgway, J.B.; Wells, J.A.; Carter, P. Stable heterodimers from remodeling the domain interface of a homodimer using a phage display library. J. Mol. Biol., 1997, 270(1), 26-35.
106. Merchant, M.; Ma, X.; Maun, H.R.; Zheng, Z.; Peng, J.; Romero, M.; Huang, A.; Yang, N.Y.; Nishimura, M.; Greve, J.; Santell, L.; Zhang, Y.W.; Su, Y.; Kaufman, D.W.; Billeci, K.L.; Mai, E.; Moffat, B.; Lim, A.; Duenas, E.T.; Phillips, H.S.; Xiang, H.; Young, J.C.; Vande Woude, G.F.; Dennis, M.S.; Reilly, D.E.; Schwall, R.H.; Starovasnik, M.A.; Lazarus, R.A.; Yansura, D.G. Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent. Proc. Natl. Acad. Sci. USA, 2013, 110(32), E2987-2996.
107. Sampei, Z.; Igawa, T.; Soeda, T.; Okuyama-Nishida, Y.; Moriyama, C.; Wakabayashi, T.; Tanaka, E.; Muto, A.; Kojima, T.; Kitazawa, T.; Yoshihashi, K.; Harada, A.; Funaki, M.; Haraya, K.; Tachibana, T.; Suzuki, S.; Esaki, K.; Nabuchi, Y.; Hattori, K. Identification and multidimensional optimization of an asymmetric bispecific IgG antibody mimicking the function of factor VIII cofactor activity. PLoS One, 2013, 8(2), e57479.
108. Davis, J.H.; Aperlo, C.; Li, Y.; Kurosawa, E.; Lan, Y.; Lo, K.M.; Huston, J.S. SEEDbodies: Fusion proteins based on strandexchange engineered domain (SEED) CH3 heterodimers in an Fc analogue platform for asymmetric binders or immunofusions and bispecific antibodies. Protein Eng. Des. Sel., 2010, 23(4), 195-202.
109. Schuurman, J.; Van Ree, R.; Perdok, G.J.; Van Doorn, H.R.; Tan, K.Y.; Aalberse, R.C. Normal human immunoglobulin G4 is bispecific: It has two different antigen-combining sites. Immunology, 1999, 97(4), 693-698.
110. Davis, S.; Smith, E.; Macdonald, D.; Olson, K.L. Readily isolated bispecific antibodies with native immunoglobulin format. WO 2010, 151792. December 29, 2011.
111. Salfeld, J.G. Isotype selection in antibody engineering. Nat. Biotechnol., 2007, 25(12), 1369-1372.
112. Salmon, J.E.; Edberg, J.C.; Brogle, N.L.; Kimberly, R.P. Allelic polymorphisms of human Fc gamma receptor IIA and Fc gamma receptor IIIB. Independent mechanisms for differences in human phagocyte function. J. Clin. Invest., 1992, 89(4), 1274-1281.
113. Warmerdam, P.A.; van de Winkel, J.G.; Vlug, A.; Westerdaal, N.A.; Capel, P.J.A single amino acid in the second Ig-like domain of the human Fcγ receptor II is critical for human IgG2 binding. J. Immunol., 1991, 147(4), 1338-1343.
114. Siberil, S.; Dutertre, C.A.; Boix, C.; Bonnin, E.; Menez, R.; Stura, E.; Jorieux, S.; Fridman, W.H.; Teillaud, J.L. Molecular aspects of human FcγR interactions with IgG: Functional and therapeutic consequences. Immunol. Lett., 2006, 106(2), 111-118.
115. Leabman, M.K.; Meng, Y.G.; Kelley, R.F.; DeForge, L.E.; Cowan, K.J.; Iyer, S. Effects of altered FcγR binding on antibody pharmacokinetics in cynomolgus monkeys. MAbs, 2013, 5(6), 896-903.
116. Chatenoud, L.; Ferran, C.; Legendre, C.; Thouard, I.; Merite, S.; Reuter, A.; Gevaert, Y.; Kreis, H.; Franchimont, P.; Bach, J.F. In vivo cell activation following OKT3 administration. Systemic cytokine release and modulation by corticosteroids. Transplantation, 1990, 49(4), 697-702.
117. Xu, D.; Alegre, M. L.; Varga, S.S.; Rothermel, A.L.; Collins, A.M.; Pulito, V.L.; Hanna L.S.; Dolan, K.P.; Parren, P.W.; Bluestone, J.A.; Jolliffe, L.K.; Zivin R.A. In vitro characterization of five humanized OKT3 effector function variant antibodies. Cell. Immunol., 2000, 200(1), 16-26.
118. Herold, K.C.; Hagopian, W.; Auger, J.A.; Poumian-Ruiz, E.; Taylor, L.; Donaldson, D.; Gitelman, S.E.; Harlan, D.M.; Xu, D.; Zivin, R.A.; Bluestone, J.A. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N. Engl. J. Med., 2002, 346(22), 1692-1698.
119. Chao, D.T.; Ma, X.; Li, O.; Park, H.; Law, D. Functional characterization of N297A, a murine surrogate for low-Fc binding anti-human CD3 antibodies. Immunol. Invest., 2009, 38(1), 76-92.
120. Cole M.S.; Anasetti, C.; Tso J.Y. Human IgG2 variants of chimeric anti-CD3 are nonmitogenic to T cells. J. Immunol., 1997, 159(7), 3613-3621.
121. Woodle, E.S.; Xu, D.; Zivin, R.A.; Auger, J.; Charette, J.; O’Laughlin, R.; Peace, D.; Jollife, L.K.; Haverty T.; Bluestone J.A.; Thistlethwaite, J.R., Jr. Phase I trial of a humanized, Fc receptor non-binding OKT3 antibody, huOKT3γ1(Ala-Ala) in the treatment of acute renal allograft rejection. Transplantation, 1999, 68(5), 608-616.
122. Keymeulen, B.; Vandemeulebroucke, E.; Ziegler, A.G.; Mathieu, C.; Kaufman, L.; Hale, G.; Gorus, F.; Goldman, M.; Walter, M.; Candon, S.; Schandene, L.; Crenier, L.; De Block, C.; Seigneurin, J.M.; De Pauw, P.; Pierard, D.; Weets, I.; Rebello, P.; Bird, P.; Berrie E.; Frewin M.; Waldmann H.; Bach J.F.; Pipeleers D.; Chatenoud L. Insulin needs after CD3-antibody therapy in newonset type 1 diabetes. N. Engl. J. Med., 2005, 352(25), 2598-2608.
123. Wing, M.G.; Moreau, T.; Greenwood, J.; Smith, R.M.; Hale, G.; Isaacs, J.; Waldmann, H.; Lachmann, P.J.; Compston, A. Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: involvement of CD16 (FcγRIII) and CD11a/CD18 (LFA-1) on NK cells. J. Clin. Invest., 1996, 98(12), 2819-2826.
124. Newman, R.; Hariharan, K.; Reff, M.; Anderson D.R.; Braslawsky, G.; Santoro, D.; Hanna, N.; Bugelski, P.J.; Brigham-Burke, M.; Crysler, C.; Gagnon, R.C.; Dal Monte, P.; Doyle, M.L.; Hensley, P.C.; Reddy, M.P.; Sweet, R.W.; Truneh, A. Modification of the Fc region of a primatized IgG antibody to human CD4 retains its ability to modulate CD4 receptors but does not deplete CD4(+) T cells in chimpanzees. Clin. Immunol., 2001, 98(2), 164-174.
125. Reddy, M.P.; Kinney, C.A.; Chaikin, M.A.; Payne, A.; Fishman-Lobell, J.; Tsui, P.; Dal Monte, P.R.; Doyle, M.L.; Brigham-Burke, M.R.; Anderson, D.; Reff, M.; Newman, R.; Hanna, N.; Sweet, R.W.; Truneh, A. Elimination of Fc receptor-dependent effector functions of a modified IgG4 monoclonal antibody to human CD4. J. Immunol., 2000, 164(4), 1925-1933.
126. Kremer, J.M.; Westhovens, R.; Leon, M.; Di Giorgio, E.; Alten, R.; Steinfeld, S.; Russell, A.; Dougados, M.; Emery, P.; Nuamah, I.F.; Williams, G.R.; Becker, J.C.; Hagerty, D.T.; Moreland, L.W. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N. Engl. J. Med., 2003, 349(20), 1907-1915.
127. Davis, P.M.; Abraham, R.; Xu, L.; Nadler, S.G.; Suchard, S.J. Abatacept binds to the Fc receptor CD64 but does not mediate complement-dependent cytotoxicity or antibody-dependent cellular cytotoxicity. J. Rheumatol., 2007, 34(11), 2204-2210.
128. Boumpas, D.T.; Furie, R.; Manzi, S.; Illei, G.G.; Wallace, D.J.; Balow, J.E.; Vaishnaw, A.; Group, B.G.L.N.T. A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum., 2003, 48(3), 719-727.
129. Socinski, M.A.; Scappaticci, F.A.; Samant, M.; Kolb, M.M.; Kozloff, M.F. Safety and efficacy of combining sunitinib with bevacizumab + paclitaxel/carboplatin in non-small cell lung cancer. J. Thorac. Oncol., 2010, 5(3), 354-360.
130. Meyer, T.; Robles-Carrillo, L.; Robson, T.; Langer, F.; Desai, H.; Davila, M.; Amaya, M.; Francis, J.L.; Amirkhosravi, A. Bevacizumab immune complexes activate platelets and induce thrombosis in FCGR2A transgenic mice. J. Thromb. Haemost., 2009, 7(1), 171-181.
131. Xie, J.H.; Yamniuk, A.P.; Borowski, V.; Kuhn, R.; Susulic, V.; Rex-Rabe, S.; Yang, X.; Zhou, X.; Zhang, Y.; Gillooly, K.; Brosius, R.; Ravishankar, R.; Waggie, K.; Mink, K.; Price, L.; Rehfuss, R.; Tamura, J.; An, Y.; Cheng, L.; Abramczyk, B.; Ignatovich, O.; Drew, P.; Grant, S.; Bryson, J.W.; Suchard, S.; Salter-Cid, L.; Nadler, S.; Suri, A. Engineering of a novel anti-CD40L domain antibody for treatment of autoimmune diseases. J. Immunol., 2014, 192(9), 4083-4092.
132. Robles-Carrillo, L.; Meyer, T.; Hatfield, M.; Desai, H.; Davila, M.; Langer, F.; Amaya, M.; Garber, E.; Francis, J.L.; Hsu, Y.M.; Amirkhosravi, A. Anti-CD40L immune complexes potently activate platelets in vitro and cause thrombosis in FCGR2A transgenic mice. J. Immunol., 2010, 185(3), 1577-1583.
133. Williams, K.L.; Sukupolvi-Petty, S.; Beltramello, M.; Johnson, S.; Sallusto, F.; Lanzavecchia, A.; Diamond, M.S.; Harris, E. Therapeutic efficacy of antibodies lacking Fcγ receptor binding against lethal dengue virus infection is due to neutralizing potency and blocking of enhancing antibodies PLoS Pathog., 2013, 9(2), e1003157.
134. Tavakoli-Keshe, R.; Phillips, J.J.; Turner, R.; Bracewell, D.G. Understanding the relationship between biotherapeutic protein stability and solid-liquid interfacial shear in constant region mutants of IgG1 and IgG4. J. Pharm. Sci., 2014, 103(2), 437-444.
135. Gong, R.; Vu, B.K.; Feng, Y.; Prieto, D.A.; Dyba, M.A.; Walsh, J.D.; Prabakaran, P.; Veenstra, T.D.; Tarasov, S.G.; Ishima, R.; Dimitrov, D.S. Engineered human antibody constant domains with increased stability. J. Biol. Chem., 2009, 284(21), 14203-14210.
136. Harding, F.A.; Stickler, M.M.; Razo, J.; DuBridge, R.B. The immunogenicity of humanized and fully human antibodies: Residual immunogenicity resides in the CDR regions. MAbs, 2010, 2(3), 256-265.
137. Jawa, V.; Cousens, L.P.; Awwad, M.; Wakshull, E.; Kropshofer, H.; De Groot, A.S. T-cell dependent immunogenicity of protein therapeutics: Preclinical assessment and mitigation. Clin. Immunol., 2013, 149(3), 534-555.
138. Steere, A.C.; Klitz, W.; Drouin, E.E.; Falk, B.A.; Kwok, W.W.; Nepom, G.T.; Baxter-Lowe, L.A. Antibiotic-refractory Lyme arthritis is associated with HLA-DR molecules that bind a Borrelia burgdorferi peptide. J. Exp. Med., 2006, 203(4), 961-971.
139. Delluc, S.; Ravot, G.; Maillere, B. Quantitative analysis of the CD4 T-cell repertoire specific to therapeutic antibodies in healthy donors. FASEB J., 2011, 25(6), 2040-2048.
140. De Groot, A. S.; Moise, L.; McMurry, J.A.; Wambre, E.; Van Overtvelt, L.; Moingeon P.; Scott, D.W.; Martin, W. Activation of natural regulatory T cells by IgG Fc-derived peptide “Tregitopes”. Blood, 2008, 112(8), 3303-3311.
141. De Groot, A.S.; Martin, W. Reducing risk, improving outcomes: Bioengineering less immunogenic protein therapeutics. Clin. Immunol., 2009, 131(2), 189-201.
142. Guilliams, M.; Bruhns, P.; Saeys, Y.; Hammad, H.; Lambrecht, B.N. The function of Fcγ receptors in dendritic cells and macrophages. Nat. Rev. Immunol., 2014, 14(2), 94-108.
143. Zheng, Y.; Scheerens, H.; Davis, J.C., Jr.; Deng, R.; Fischer, S.K.; Woods, C.; Fielder, P.J.; Stefanich, E.G. Translational pharmacokinetics and pharmacodynamics of an FcRn-variant anti-CD4 monoclonal antibody from preclinical model to phase I study. Clin. Pharmacol. Ther., 2011, 89(2), 283-290.
144. Andersen, J.T.; Daba, M.B.; Berntzen, G.; Michaelsen, T.E.; Sandlie, I. Cross-species binding analyses of mouse and human neonatal Fc receptor show dramatic differences in immunoglobulin G and albumin binding. J. Biol. Chem., 2010, 285(7), 4826-4836.
145. Bruhns, P. Properties of mouse and human IgG receptors and their contribution to disease models. Blood, 2012, 119(24), 5640-5649.
146. Junttila, T.T.; Parsons, K.; Olsson, C.; Lu, Y.; Xin, Y.; Theriault, J.; Crocker, L.; Pabonan, O.; Baginski, T.; Meng, G.; Totpal, K.; Kelley, R.F.; Sliwkowski, M.X. Superior in vivo efficacy of afucosylated trastuzumab in the treatment of HER2-amplified breast cancer. Cancer Res., 2010, 70(11), 4481-4489.
147. Li, F.; Ravetch, J.V. Inhibitory Fcγ receptor engagement drives adjuvant and anti-tumor activities of agonistic CD40 antibodies. Science, 2011, 333(6045), 1030-1034.
148. Smith, P.; DiLillo, D.J.; Bournazos, S.; Li, F.; Ravetch, J.V. Mouse model recapitulating human Fcγ receptor structural and functional diversity. Proc. Natl. Acad. Sci. USA, 2012, 109(16), 6181-6186.